TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TNF Blocking Therapies and Immunomonitoring in Patients with Inflammatory Bowel Disease
Authors
Keywords
-
Journal
MEDIATORS OF INFLAMMATION
Volume 2014, Issue -, Pages 1-7
Publisher
Hindawi Limited
Online
2014-03-19
DOI
10.1155/2014/172821
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Review article: immunogenicity of anti-TNF biologics in IBD - the role of patient, product and prescriber factors
- (2013) A. C. Moss et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future
- (2013) S. Danese et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
- (2013) Niels Vande Casteele et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
- (2013) Fernando S. Velayos et al. Clinical Gastroenterology and Hepatology
- Targeting TNF-α for the treatment of inflammatory bowel disease
- (2013) Thomas Billiet et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab
- (2013) Bella Ungar et al. GUT
- Serum Adalimumab Concentration and Clinical Remission in Patients with Crohnʼs Disease
- (2013) Yi-Lin Chiu et al. INFLAMMATORY BOWEL DISEASES
- Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease
- (2013) Stephane Paul et al. INFLAMMATORY BOWEL DISEASES
- Pharmacokinetics of Infliximab in Children with Moderate-to-Severe Ulcerative Colitis
- (2013) Omoniyi J. Adedokun et al. INFLAMMATORY BOWEL DISEASES
- Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease
- (2013) Hirotsugu Imaeda et al. JOURNAL OF GASTROENTEROLOGY
- TNFR2 Is Critical for the Stabilization of the CD4+Foxp3+ Regulatory T Cell Phenotype in the Inflammatory Environment
- (2013) X. Chen et al. JOURNAL OF IMMUNOLOGY
- Infliximab Inhibits Activation and Effector Functions of Peripheral Blood T Cellsin vitrofrom Patients with Clinically Active Ulcerative Colitis
- (2013) R. Dahlén et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Letter: detection of infliximab levels and anti-infliximab antibodies - comparison of three different assays
- (2012) E. Parussini ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Letter: detection of infliximab levels and anti-infliximab antibodies - comparison of three different assays; authors’ reply
- (2012) D. J. Buurman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays
- (2012) N. Vande Casteele et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
- (2012) Kavinderjit S Nanda et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
- (2012) Shomron Ben–Horin et al. Clinical Gastroenterology and Hepatology
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
- (2012) I Ordás et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease
- (2012) Casper Steenholdt et al. INFLAMMATORY BOWEL DISEASES
- Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management
- (2012) Axel Dignass et al. Journal of Crohns & Colitis
- Paradoxical inflammation induced by anti-TNF agents in patients with IBD
- (2012) Isabelle Cleynen et al. Nature Reviews Gastroenterology & Hepatology
- Review article: infliximab for Crohn’s disease treatment - shifting therapeutic strategies after 10 years of clinical experience
- (2011) S. Danese et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- A British Society of Paediatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease
- (2011) R. K. Russell et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: remission rates achievable by current therapies for inflammatory bowel disease
- (2011) L. Peyrin-Biroulet et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
- (2011) Vincent Billioud et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Assessing Response and Loss of Response to Biological Therapies in IBD
- (2011) Henit Yanai et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Th17-related cytokines: new players in the control of chronic intestinal inflammation
- (2011) Ivan Monteleone et al. BMC Medicine
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
- (2011) Adedigbo A. Fasanmade et al. CLINICAL THERAPEUTICS
- Contrasting effects of TNF and anti-TNF on the activation of effector T cells and regulatory T cells in autoimmunity
- (2011) Xin Chen et al. FEBS LETTERS
- Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease
- (2011) Benjamin Pariente et al. INFLAMMATORY BOWEL DISEASES
- Retrieval of Serum Infliximab Level by Shortening the Maintenance Infusion Interval Is Correlated with Clinical Efficacy in Crohnʼs Disease
- (2011) Toshifumi Hibi et al. INFLAMMATORY BOWEL DISEASES
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Outcome Following Infliximab Therapy in Children With Ulcerative Colitis
- (2010) Jeffrey S Hyams et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful
- (2010) S. Ben-Horin et al. GUT
- Clinical scenarios in IBD: Optimizing the use of conventional and biologic agents
- (2010) Stephen B. Hanauer et al. INFLAMMATORY BOWEL DISEASES
- Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics
- (2010) William J. Sandborn et al. INFLAMMATORY BOWEL DISEASES
- The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
- (2010) A. Dignass et al. Journal of Crohns & Colitis
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
- (2010) Casper Steenholdt et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
- (2009) Adedigbo A. Fasanmade et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
- (2009) Konstantinos Karmiris et al. GASTROENTEROLOGY
- Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis
- (2009) C H Seow et al. GUT
- Incidence and clinical significance of immunogenicity to infliximab in Crohnʼs disease
- (2009) Andrea Cassinotti et al. INFLAMMATORY BOWEL DISEASES
- Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn’s disease
- (2008) R. L. WEST et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
- (2008) Laurent Peyrin–Biroulet et al. Clinical Gastroenterology and Hepatology
- Withdrawal of Immunosuppression in Crohn's Disease Treated With Scheduled Infliximab Maintenance: A Randomized Trial
- (2008) Gert Van Assche et al. GASTROENTEROLOGY
- Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
- (2008) F Schnitzler et al. GUT
- Population Pharmacokinetics of Infliximab in Patients With Ankylosing Spondylitis
- (2008) Zhenhua Xu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease
- (2007) Mark A. Ainsworth et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search